Modalis to Wipe Out Retained Earnings Deficit via Capital Reduction

The latest announcement is out from Modalis Therapeutics Corporation ( (JP:4883) ).

Modalis Therapeutics plans to restructure its equity accounts by reducing its stated capital by ¥1,124,612,444 and its capital reserves by ¥1,124,612,443, reallocating these amounts to other capital surplus. The move is aimed at repairing a retained earnings deficit of ¥2,249,224,887 recorded at the end of 2025 and is scheduled to take effect on May 15, 2026, subject to shareholder approval and completion of creditor procedures.

By transferring the increased other capital surplus to retained earnings brought forward, the company intends to eliminate its accumulated deficit and bring retained earnings to zero without changing total net assets or the number of shares outstanding. Management states that the measures will not affect business performance or per-share net asset value, suggesting the initiative is an accounting and capital policy adjustment designed to improve financial soundness and enhance flexibility for future capital strategy rather than an operational shift.

The most recent analyst rating on (JP:4883) stock is a Hold with a Yen57.00 price target. To see the full list of analyst forecasts on Modalis Therapeutics Corporation stock, see the JP:4883 Stock Forecast page.

More about Modalis Therapeutics Corporation

Modalis Therapeutics Corporation is a biotechnology company listed on the Tokyo Stock Exchange that focuses on developing gene therapy-based treatments. The company operates in the life sciences sector, where access to flexible financing and a solid balance sheet are critical to sustaining long development timelines and managing R&D investment risk.

Average Trading Volume: 826,925

Technical Sentiment Signal: Sell

Current Market Cap: Yen5.07B

See more data about 4883 stock on TipRanks’ Stock Analysis page.